Related Experiment Video

Updated: May 30, 2026

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts
11:19

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts

Published on: October 9, 2016

Small molecule inhibitors of STAT3 for cancer therapy

M Zhao1, B Jiang, F-H Gao

  • 1NO.3 People's Hospital affiliated to Shanghai Jiao-Tong University School of Medicine, Shanghai 201900, China.

Current Medicinal Chemistry
|August 10, 2011
PubMed

Insights

Signal transducer and activator of transcription 3 (STAT3) is a key driver in many cancers. This review covers small molecule inhibitors targeting STAT3 for novel cancer therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Aberrant activation of Signal transducer and activator of transcription 3 (STAT3) is implicated in the pathogenesis of numerous human cancers.
  • Constitutive STAT3 activity promotes tumor growth, survival, and immune evasion by regulating target genes involved in proliferation, apoptosis, and angiogenesis.

Purpose of the Study:

  • To provide a comprehensive review of small molecular inhibitors targeting STAT3 for cancer therapy.
  • To discuss the rationale and current landscape of developing STAT3 as a direct molecular target for anticancer strategies.

Main Methods:

  • Literature review of experimental research papers on small molecular inhibitors of STAT3.
  • Analysis of studies investigating STAT3 as a cancer therapeutic target.

Main Results:

  • STAT3 is a validated molecular target in oncology due to its critical role in tumor development.
  • Various small molecular weight compounds have been developed to inhibit STAT3 signaling pathways.
  • The review consolidates information on existing inhibitory modalities against STAT3.

Conclusions:

  • Targeting STAT3 with small molecule inhibitors represents a promising therapeutic strategy for various cancers.
  • Further development of STAT3-targeted agents holds potential for novel anticancer drug discovery.
  • Disrupting oncogenic STAT3 signaling offers a direct approach to combat cancer progression.

More Related Videos

Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome07:23

Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome

Published on: June 15, 2016

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...